

**Financial Result
of 3rd Quarter
Fiscal Year Ending Mar 2016**

 **KAWASUMI LABORATORIES, INC.**

February 10, 2016

3rd Quarter Business Result

Consolidated


Unit : Billion YEN

	Q3 Apr-Dec 2014	Q3 Apr-Dec 2015	Increase / Decrease	Ratio
Net sales	21.13	21.14	+0.00	0.0%
Gross profit	7.06	7.52	+0.46	6.5%
Operating income	1.09	1.59	+0.51	46.4%
Ordinary income	1.47	1.70	+0.23	15.3%
Net income	0.81	1.24	+0.43	52.6%

Exchange Rate	Q3 Apr-Dec 2014	Q3 Apr-Dec 2015
US\$	107.8	121.6
EUR	140.4	134.0
Baht	3.32	3.47

- Net sales stayed at the same level.
(Decreased : OEM products. / Growth : Blood bags and Blood Tubing Lines.)
- Gross profit increased 0.46 billion Yen by Exchange rate effect and Cost reduction.
- Operating income increased 0.51 billion Yen by increase of Gross profit and SG&A expense decrease.

Net Seles (By Segment)



【Blood Transfusion and Endovascular】


- Increase Blood Bags
- Decrease Infusion Set (OEM)

【Hemodialysis and Plasmapheresis】

- Increase Blood Tubing Line, Dialyzer for overseas
- Decrease A.V. Fistula Needles (OEM)

Net Sales (By Region)

(Billion YEN)



【Japan】

- Increase
Blood Tubing Lines
- Decrease
Normal Saline Solution


【Overseas】

- Increase
Blood Bags, Dialyzer
- Decrease
A.V. Fistula Needles (OEM)
Infusion Set (OEM)

FYE Mar 2016

Gross Profit Variance Analysis

(Billion YEN)



SG&A Expenses

Consolidated

Unit : Billion YEN

	Q3 Apr-Dec 2014	Q3 Apr-Dec 2015	Increase / Decrease
Salaries & Wages	2.34	2.40	0.06
Logistical costs	0.78	0.73	-0.05
R&D Expenses	0.72	0.48	-0.24
Others	2.13	2.31	0.18
Total	5.97	5.92	-0.05

- R&D expenses decreased since consignment experimental and research expense decreased.
- Others increased since there was the expenditure of production relocation.



Inquiries:

Kawasumi Laboratories, Inc.

Corporate Planning

TEL : +81 (0) 3-5769-2698

Email : webmaster1@kawasumi.jp